Podcasts about Pharma

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Podcast: ICS Arabia PodcastEpisode: Pharma OT Security | 64Pub date: 2025-12-26Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationWe're joined by Andre Froneman, OT Solutions Specialist at Datacentrix — a cybersecurity professional with hands-on experience across the pharma, mining, automotive, and energy sectors.In this episode, we dive deep into pharmaceutical OT cybersecurity, exploring how one of the world's most sensitive industries protects its operations, data, and intellectual property from cyber threats.

Send us a textIn this episode, the boys present another of their popular Dynamite Conspiracies episodes, in which they ask if there is a "Sugar cover-up"?But what are your thoughts on this topic?Do you agree with Tony and Tayo on this?Or do you have other thoughts?Items used during the show:The "Sugar Cover-Up": In the 1960s, the sugar industry paid Harvard scientists (Project 226) to shift the blame for heart disease from sugar to saturated fat. This led to the "Low Fat" craze, where manufacturers removed fat from food but replaced it with massive amounts of sugar to make it taste good.The "Ancel Keys" Effect: Discuss the "Seven Countries Study." Keys famously cherry-picked data to prove fat was bad, conveniently leaving out countries (like France and West Germany) that ate lots of fat but had low heart disease.The "Profit" Motive: A cured diabetic buys no drugs. A managed diabetic is a customer for life. Is the push against "Keto" (which can reverse Type 2) actually about protecting pharmaceutical revenue?-https://diabetesjournals.org/care/article/34/Supplement_2/S132/28705/Hypoglycemia-and-Cardiovascular-Risks-https://news.un.org/en/story/2023/07/1138732Tune in and listen to the discussion. Please share your thoughts on these subjects.Although we greatly appreciate effusive praise on our Facebook page, we also welcome any feedback you might care to share, so please feel free to leave it. If your comments cause outrage or uproar, we'll likely have you on the show, as we're a bit unconventional in that regard.

Was, wenn eines der wirksamsten Heilmittel nie aus der Apotheke kam – und genau darüber jahrelang nicht gesprochen werden durfte? In diesem augenöffnenden Gespräch mit Dr. Roman Szeliga, Arzt und ehemaligem Pharma-Insider, öffnet sich Dir ein Blick hinter die Kulissen der Medizin. Du erfährst, warum Heilung weit mehr ist als Wirkstoffe und weshalb eine zutiefst menschliche Komponente systematisch unterschätzt wurde. Dr. Szeliga teilt Erfahrungen aus Krankenhäusern, die berühren, irritieren und ein völlig neues Verständnis von Gesundheit erahnen lassen. Am Ende bleibt eine Erkenntnis, die alles verändert – und die Dich unweigerlich fragen lässt, was Dir über Deine Gesundheit bisher verschwiegen wurde. Dr. Roman Szeligas Buch: "Hirn mit Herz hat Hand und Fuß" https://amzn.to/4geZnhL   Die geäußerten Meinungen und Aussagen dienen ausschließlich Bildungs- und Informationszwecken, ersetzen jedoch keine therapeutische oder medizinische Beratung. Bereit Dein Genie zu entdecken? Lebe selbstbewusster, freier & erfolgreicher mit genialen Video-Kursen aus unserer Online-Akademie: https://akademie.maximmankevich.com/  

En la entrevista del programa La Miel en tu radio conversamos con Miguel Ángel Rodriguez - Director de Apicultura - VETO-PHARMA 27/12/2025 con quien conversamos sobre su participación en la próxima Meliza 2026 del 20 al 22 de febrero de 2026 en Zamora - España y todo el balance en torno a los desarrollos de su empresa.

Happy holidays once again! This is being aired the day after Christmas, or on Boxing Day for those who are in places that do a thing called Boxing Day. I guess it has something to do with giving boxes, or having boxes, or maybe relatives boxing one another after spending time together over the holidays. Whatever it is, hope you have a happy one. The actual origins, according to Wikipedia, seems to be around the mid 1700s when “traditionally on this day tradespeople, employees, etc., would receive presents or gratuities (a ‘Christmas box') from their customers or employers.” So maybe one of the earlier manifestations of customer and employee experience. One of the things that I love about doing experience design is how relatively small things can make someone feel like a superhero. Little acts of experience design can make a big difference in people's days and even their lives. And isn't that what it is all about, including the holidays? Whatever you believe or don't believe regarding the holidays, being mindful of extending small acts of kindness or doing something that is relatively simple to make a huge impact. Which is a perfect thing to keep in mind for our show today. My guest on Experience by Design is Erika Sinner. Erika brings a lot of compassion and empathy to the world. In fact, she prefers the title of Chief Empathy Officer. Her book Pets are Family emphasizes the importance of pet bereavement policies in organizations. This is just one part of her efforts to bring more empathy to the workplace. She also is the CEO and Founder of Directorie, “a(n) agency that connects seasoned commercial, marketing, and market access experts” with organizations that are under-resourced and overworked. If that wasn't enough, she now is the Chief Empathy Officer of Tiny Super Heroes, which makes children who are facing unique medical challenges to feel like the superheroes that they are. As their website states, “We're setting out to transform hospital culture - one hospital at a time - because every child's clinical journey should be filled with strength, hope, and a little more fun.”As part of Tiny Super Heroes, children get their own superhero capes and get badges to mark the medical treatments they receive as well as other accomplishments. It is all at no cost, and made possible through the donations of individuals and organizations, and aims to reach all 226 children's hospitals in the country.We talk about Erika's personal journey and struggles that led her to her work as a founder Directorie and now CEO of Tiny Super Heroes. We also talk about the importance of play in the workplace as a way of creating a sense of safety and trust. Talking about culture as a leader isn't enough; leaders need to take the necessary steps to create a place where employees don't dread Sunday nights because they have to go to work on Monday. She discusses the importance of company culture and employee commitment in attracting top talent, especially for Gen Z and Gen Alpha who prioritize making a difference.Erika discusses the positive impact of the Tiny Super Heroes program on children with medical conditions, highlighting how it helps reduce anxiety and improve clinical outcomes by transforming medical experiences into fun missions. The program has online support groups for parents, which currently have around 60,000 members. Healthcare providers also benefit from the program by creating a more positive and playful environment in hospitals. In this way, it is really an experience design that impacts the healthcare ecosystem.So on this Boxing Day, you can listen to this episode and head over to the Tiny Super Heroes website to give a gift that can make all the difference.Erika Sinner: https://www.linkedin.com/in/erikasinner/Erika Sinner Website: https://www.erikasinner.org/“Pets are Family” Book: https://www.erikasinner.org/for-bookstoreDirectorie: https://www.directorie.com/Tiny Super Heroes: https://tinysuperheroes.com/

Was waren die heissesten Themen an den Aktienmärkten im Jahr 2025?

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here! Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeThe ultimate unholy union is government and healthcare. President Trump has put out some words on government and healthcare, and President Trump, is a good friend of big Pharma.Episode Links:Democrat Senator Peter Welch on Obamacare: "We did fail to bring down the cost of healthcare."American doctor goes over how Barack Obama destroyed American HealthcareObamacare is only 7% of Americans. Literally almost 100% of Americans need relief from their health care policy premiums, not just 7%. We need to have free market solutions that bring down the cost of health care for every American, not just the 7%.The Danish Cow Crisis: Bill Gates, “Bovaer,” and the War on Nature. In Denmark, farmers are raising alarms after a new climate-driven feed additive called Bovaer became mandatory on October 1, 2025.Virtually everything that Obama promised about Obamacare was a lie. Now the country is stuck dealing with the ramifications. Instead of taking responsibility, Democrats have shut down the government and are demanding that Republicans fix what they broke.

On this Christmas Eve edition of Badlands Daily, CannCon and Ashe in America take to the mic for a spirited, heartfelt, and wide-ranging conversation as they close out the holiday week with the Badlands community. The show blends festive moments with hard-hitting commentary, touching on government overreach, Big Pharma corruption, taxpayer-funded research scams, and the broader push to “equalize” America at the expense of its people. The hosts engage directly with the audience through rants and shout-outs, reflect on the year that was, and discuss ongoing investigations, election integrity issues, and the growing ability to speak more openly as censorship loosens. Along the way, they share holiday wishes, upcoming programming notes, and gratitude for the Badlands family that continues to show up every day. A Christmas Eve broadcast that balances humor, conviction, and community, this episode captures the spirit of Badlands Daily - truth-seeking, unapologetic, and rooted in faith, freedom, and fellowship.

Nifty opened with hope but slammed straight into a wall at 26,200. Why does this specific number keep rejecting the Bulls? The data shows "Aggressive Call Writing"—meaning the big players are betting heavily against a breakout. We are sitting right below the highest closing level of the last year (26,220), and the tension is building. While Media and Realty stocks are fighting back, Oil & Gas and Pharma are dragging us down. Tonight, Neel Parekh decodes the "Max Call OI" mystery and gives you the exact levels (26,050 vs 26,325) that will decide the next big move. Don't get caught on the wrong side of the breakout.

Nifty opened with hope but slammed straight into a wall at 26,200. Why does this specific number keep rejecting the Bulls? The data shows "Aggressive Call Writing"—meaning the big players are betting heavily against a breakout. We are sitting right below the highest closing level of the last year (26,220), and the tension is building. While Media and Realty stocks are fighting back, Oil & Gas and Pharma are dragging us down. Tonight, Neel Parekh decodes the "Max Call OI" mystery and gives you the exact levels (26,050 vs 26,325) that will decide the next big move. Don't get caught on the wrong side of the breakout.

Nifty opened with hope but slammed straight into a wall at 26,200. Why does this specific number keep rejecting the Bulls? The data shows "Aggressive Call Writing"—meaning the big players are betting heavily against a breakout. We are sitting right below the highest closing level of the last year (26,220), and the tension is building. While Media and Realty stocks are fighting back, Oil & Gas and Pharma are dragging us down. Tonight, Neel Parekh decodes the "Max Call OI" mystery and gives you the exact levels (26,050 vs 26,325) that will decide the next big move. Don't get caught on the wrong side of the breakout.

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Read our Macrovey deal analysis (closed) on KingscrowdRobotics hype is everywhere—but who actually makes robots work on real warehouse floors? In this episode, Chris sits down with Macrovey Director of Business Development Matt Labinski to unpack how Macrovey designs fully autonomous, material-handling systems that act like a warehouse “Robotics OS.” We start with what Macrovey is and isn't (00:03)—the company doesn't manufacture robots, it integrates best-in-class OEMs through proprietary orchestration software. Matt explains the model (00:32): up-front design + install and recurring software/maintenance—plus a Robots-as-a-Service option that lowers CapEx. We dive into who buys (06:28): e-commerce, 3PLs, pharma, defense (U.S. Air Force) and even smaller 10k–100k sq ft facilities. Category context (07:31): warehouse robotics penetration is still surprisingly low; Macrovey targets the SMB/mid-market others ignore. We cover why OEMs and warehouses need an integrator (09:09), the sales cycle and deal sizes (12:22)—from $50k pilots to $3M+ programs—and how modular, mobile systems (25:03) move with demand. Finally, we hit the AI layer (27:31): machine learning that optimizes slotting, picking, and vision-based QA. If you want exposure to warehouse autonomy without betting on a single robot, Macrovey's middle-layer, recurring-revenue approach may be the de-risked way to play it.

This week, Isabel brings together three expert voices for an end-of-year round-up, reflecting on the moments that shaped healthcare and life sciences in 2025. Joined by Jonathan Sackier, Chairman, Medical Advisory Board, EMJ, Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, and omnichannel expert Yacin Marzouki, the conversation looks back on a year defined by both disruption and progress. Across the episode, the contributors share their perspectives on the biggest setbacks and standout successes of the past 12 months, from regulatory uncertainty and access challenges to collaboration, innovation and scientific momentum. They also reflect on the lessons 2025 has taught them, and what those insights mean for patients, industry and the year ahead. Speaker bios Hanna Svanbäck Executive Director for Neuroscience, Eli Lilly With over 15 years at Eli Lilly, Hanna leads Neuroscience operations across the UK, Ireland and the Nordics, driving scientific innovation and patient-centred research. Jonathan Sackier Chairman, Medical Advisory Board, EMJ Jonathan is a surgeon by training and a founding partner of many start-ups in the medical technology space, as well as being the creator of the world's first operating room robot. Yacin Marzouki  Omnichannel expert Within the pharmaceutical sector, Yacin specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

2025 – what a year that was for medical marketing.So many events and developments contributed to headlines in not only MM+M but mainstream outlets as well.Chief among them was the confirmation of Robert F. Kennedy Jr. as HHS Secretary, which signaled the direction that the second Trump administration would take on health policy.Not to be outdone, AI had a sizable impact, too. The momentum behind AI affected how millions consume information, do their jobs and even the ads they see on a daily basis.  Additionally, the closing of Omnicom's takeover of IPG sent another shockwave through adland. Though medical marketing shops may be more insulated than consumer agencies, they were not spared.This week, I'm joined by editor-in-chief Jameson Fleming, editor-at-large Steve Madden, pharma editor Lecia Bushak and reporter Heerea Rikhraj so the MM+M editorial team can say ‘goodbye' to 2025 and ‘hello' to 2026 in our final episode of the year.And once again, in lieu of the Trends segment, we bring you an interview from our recent AI Deciphered conference, this time with health futurist John Duffield. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Eastman Kodak Company is ready for its closeup. The 130-year-old film company made big moves this year to bulk up its balance sheet and push into a brand new field - pharmaceuticals. Kodak completed a pension reversion in November, which unlocked $1 billion. The funds create a new pension fund, bringing debt down to $200 million, and put $300 million in cash on the balance sheet. The goal now - innovate. Kodak has always been a chemical company. Executives are using that expertise to move into the pharmaceutical industry. FOX Business's Lydia Hu speaks with Eastman Kodak Company executive chairman and chief executive officer Jim Continenza about how, while the company is still focused on film, it believes it has the expertise and infrastructure to grow by delving into pharmaceuticals. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Are you a nurse or healthcare professional feeling burned out, underpaid, and stuck in a cycle of bureaucracy?Today, I reveal the 3-3-3 Framework: a blueprint specifically designed for bedside nurses who want to break into the high-paying world of Pharmaceutical and Medical Device Sales.If you are tired of missing holidays and hitting a salary ceiling, this episode explains exactly what you actually need to do to land offers like our student Sydney, who went from $68k to a $138k package.IN THIS EPISODE, YOU WILL LEARN:The 3 Reasons to Leave: Why burnout and lack of creativity are signs it's time to pivot.The 3 Barriers: Why relying on your degree and "following orders" kills your chances in sales interviews.The 3 Solutions: How to leverage your clinical edge and tap into the 10,000+ open roles in biotech right now.READY TO LAND YOUR DREAM JOB? Apply to Medical Sales University and learn how we help nurses double their income in 12 weeks: medicalsalesu.com/TIMESTAMPS00:00 - Intro: The shift from Bedside to Sales01:38 - The 3 Reasons healthcare workers are leaving (Burnout & Bureaucracy)03:13 - Why your career growth has stalled04:10 - The 3 Barriers: Why you aren't getting hired yet05:00 - The "Middle Class Mindset" trap (Degree vs. Skills)06:12 - Mindset Shift: From Compliance to Ownership09:18 - The 3 Solutions: How to finally break in10:52 - Success Story: How Sydney landed a $138k Oncology role12:50 - Why mentorship beats doing it aloneABOUT THE HOST: Dave Sterrett is the founder of Medical Sales University, the #1 program helping nurses, PTs, and healthcare professionals break into pharmaceutical and oncology sales.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US:Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #NursingCareer #PharmaSales #NurseBurnout #CareerChange #MedicalDeviceSales #HighPayingJobs #Nurselife

The Eastman Kodak Company is ready for its closeup. The 130-year-old film company made big moves this year to bulk up its balance sheet and push into a brand new field - pharmaceuticals. Kodak completed a pension reversion in November, which unlocked $1 billion. The funds create a new pension fund, bringing debt down to $200 million, and put $300 million in cash on the balance sheet. The goal now - innovate. Kodak has always been a chemical company. Executives are using that expertise to move into the pharmaceutical industry. FOX Business's Lydia Hu speaks with Eastman Kodak Company executive chairman and chief executive officer Jim Continenza about how, while the company is still focused on film, it believes it has the expertise and infrastructure to grow by delving into pharmaceuticals. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovation at IDEA, reminisces about the early days leading to the successful positioning and market shaping of luspatercept across different hematological indications. The episode features insightful contributions from Robin, Jane, and Tracy, key players from Acceleron and Celgene, who share their experiences and the collaborative efforts that enabled them to redefine the market. The discussion covers the strategic approach to overcoming competitive benchmarking, the importance of a unified messaging strategy, and the critical role of internal and external collaboration. They also reflect on the impact of their efforts on the lives of many patients and offer advice for future teams working on complex drug development projects. The episode concludes with a recognition of the rare and valuable collaborative human elements that drove the success of the Reblozyl project.Episode Timestamps;00:00 Introduction and Welcome00:27 Rick's Background and Project Overview02:31 Client Team Introductions05:32 Collaboration and Challenges13:29 Defining the Mechanism and Market Positioning23:52 Communication and Alignment27:48 Navigating Internal and External Communication33:15 Launch, Reflections, and Lessons Learned41:14 Final Thoughts and Acknowledgements Keep up with the guests;Robyn Blackburn  - Director Global Commercial Strategy CAR-T at Kite Pharmahttps://www.linkedin.com/in/robyn-blackburn-805b8b13/Jayne Butler - Director of Strategic Initiatives at Fingerpaint Brandinghttps://www.linkedin.com/in/jaynebutler/Tracey Sacco - Former SVP Global Strategic Marketing at Acceleronhttps://www.linkedin.com/in/tracey-sacco-53 2a034/Rick Ritacco - Head of Growth and Innovationhttps://www.linkedin.com/in/rritacco/ Follow Mike Rea On;Website: https://ideacollider.simplecast.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

The Eastman Kodak Company is ready for its closeup. The 130-year-old film company made big moves this year to bulk up its balance sheet and push into a brand new field - pharmaceuticals. Kodak completed a pension reversion in November, which unlocked $1 billion. The funds create a new pension fund, bringing debt down to $200 million, and put $300 million in cash on the balance sheet. The goal now - innovate. Kodak has always been a chemical company. Executives are using that expertise to move into the pharmaceutical industry. FOX Business's Lydia Hu speaks with Eastman Kodak Company executive chairman and chief executive officer Jim Continenza about how, while the company is still focused on film, it believes it has the expertise and infrastructure to grow by delving into pharmaceuticals. Learn more about your ad choices. Visit podcastchoices.com/adchoices

✅ Alles zum Thema Lithium: Hier klicken✅ Vollständiges Video von Dr. med. Michael Niels: Hier klicken

Join Eric, @EnglishNick67, @ShelleyWynter1, Steffan Pappas, @DrJoeEsposito, Santa, @TimAndrewsHere, @Autopritts, @JaredYamamoto, Greg, and George LIVE on 95.5 WSB from 3pm-7pm as they celebrate a merry Christmas during their very last show of the year with songs, trivia, laughter, joy and more! *New episodes of our sister shows: The Popcast with Tim Andrews and The Nightcap with Jared Yamamoto are available as well!

ByteDance signs a deal for a TikTok U.S. joint venture, The second Russia–Africa Partnership Ministerial Conference kicks off in Egypt, The EU agrees on a €90 billion loan to Ukraine, While the EU delays a Mercosur trade deal signing amid farmer protests, Australia launches a gun buyback after the Bondi Beach attack, Pharma companies agree to cut U.S. drug prices in a Trump administration deal, The suspect in the Brown University mass shooting and MIT professor murder is found dead, Trump Media merges with TAE in $6 billion fusion energy deal, Facebook tests limiting external links for non-verified accounts and U.K. actors vote overwhelmingly against digital scanning to train AI. Sources: Verity.News

Tune in as Glenn Hunzinger and Roel van den Akker share their outlook for pharmaceutical and life sciences dealmaking in 2026. They discuss improving market conditions, innovation driven growth, and how upcoming loss of exclusivity is shaping deal strategy.  Discussion highlights: Strong innovation, healthy balance sheets, and improving capital markets support a positive outlook for 2026 M&A is expected to remain precision-led and asset-focused, centered on differentiated science and key therapeutic areas Accelerating loss of exclusivity (2026–2029) is increasing reliance on external innovation Mid-sized deals have dominated, but clearer policy and better financing may enable larger strategic transactions As innovation globalizes, companies are sourcing assets more deliberately worldwide, with the US remaining a core life sciences hub Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Roel van den Akker, US Pharmaceutical & Life Sciences Deals Leader, PwCLinked Materials:https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Die Antibabypille war eine medizinische und gesellschaftliche Revolution, doch seit über 60 Jahren gibt es sie nur für Frauen. Wieso eigentlich? In dieser 11KM-Folge erzählt uns NDR-Wissenschaftsjournalistin Daniela Remus, warum es trotz vielversprechender Ansätze bisher nicht gelungen ist, eine Pille für den Mann auf den Markt zu bringen – und welche gesellschaftlichen Veränderungen sie bringen würde. Tickets für 11KM auf dem ersten ARD Sounds Festival am 9. Mai 2026 in Nürnberg gibt es hier. Wir freuen uns, wenn ihr mit dabei seid! https://1.ard.de/11KM_ARD_Sounds_Festival Hier geht's zur Danielas Folge bei “IQ - Wissenschaft und Forschung”: https://www.ardaudiothek.de/episode/urn:ard:episode:999f4b089b8a2754/ In dieser früheren 11KM-Folge "Ei, ei, ei, die Spermakrise” beantworten wir die Frage, warum seit Jahren immer weniger Spermien im Ejakulat zu finden sind: https://1.ard.de/11KM_Spermakrise Hier geht's zu “Liebt euch – der UNSERDING Dating Podcast”, unserem Podcast-Tipp: https://www.ardaudiothek.de/sendung/liebt-euch-der-dating-podcast/urn:ard:show:178a60183a5a9d80/ An dieser Folge waren beteiligt: Folgenautor: Max Stockinger Mitarbeit: Lukas Waschbüsch Host: Elena Kuch Produktion: Timo Lindemann, Konrad Winkler, Hanna Brünjes und Marie-Noelle Svihla Planung: Caspar von Au und Hardy Funk Distribution: Kerstin Ammermann Redaktionsleitung: Fumiko Lipp und Nicole Dienemann 11KM: der tagesschau-Podcast wird produziert von BR24 und NDR Info. Die redaktionelle Verantwortung für diese Episode liegt beim BR.

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we close out the year 2025, it's clear that the pharmaceutical and biotech industries have experienced a period of significant transformation. This year has been marked by groundbreaking drug approvals, strategic partnerships, and a focus on innovative therapies that promise to redefine patient care.One of the standout achievements this year comes from GlaxoSmithKline, which received approval from the U.S. FDA for its ultra-long-acting biologic, Exdensur, aimed at treating severe asthma with an eosinophilic phenotype in adolescents and adults. This approval underscores the growing trend toward personalized medicine and biologics, offering new hope for patients with chronic respiratory conditions by providing more sustainable and personalized treatment options.In the oncology sector, Merck's Keytruda and Astellas Pharma's Padcev have demonstrated significant overall survival benefits when used as perioperative treatments for cisplatin-eligible muscle-invasive bladder cancer. This combination therapy of a PD-1 checkpoint inhibitor and an antibody-drug conjugate highlights the evolving landscape of cancer treatment, emphasizing the role of immunotherapy and targeted therapies in improving patient outcomes in challenging cancer subtypes.However, not all developments have been positive. Hansa Biopharma faced challenges with its kidney transplant drug, imlifidase. Despite success in kidney transplant trials, it failed to achieve desired results in treating anti-glomerular basement membrane disease. This serves as a reminder of the complexities involved in drug repurposing efforts within autoimmune diseases.Alnylam Pharmaceuticals announced a significant investment to enhance its Norton, Massachusetts facility into a dedicated site for small interfering RNA (siRNA) production. This move reflects the industry's shift towards RNA-based therapies that offer targeted gene-silencing capabilities and positions Alnylam at the forefront of RNAi therapeutics production.In another promising development, ImmunityBio reported positive data from its QUILT-3.032 study on Anktiva for BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary disease. The potential expansion of Anktiva's use reinforces the importance of personalized immunotherapies in oncology.The launch of Ambros Therapeutics with $125 million in Series A funding highlights efforts to develop non-opioid pain medications already approved abroad. This initiative addresses chronic pain management without relying on opioids, potentially advancing analgesic therapies amidst the ongoing opioid crisis.In China, Fosun Pharma's acquisition of a majority stake in Green Valley Pharmaceuticals aims to revive a controversial seaweed-derived Alzheimer's medication. Despite skepticism over its efficacy, this investment signals continued innovation efforts amid growing demand for effective Alzheimer's treatments.Siemens Healthineers' partnership with Alzpath to incorporate pTau-217 antibodies into its Atellica immunoassay platforms marks a significant step forward in Alzheimer's diagnostics. This collaboration aims to enhance biomarker detection capabilities crucial for early diagnosis and intervention strategies in neurodegenerative diseases.On the strategic front, Bristol Myers Squibb entered into a substantial research agreement with Harbour BioMed valued at up to $1.1 billion. This deal underscores Big Pharma's ongoing pursuit of alliances to advance therapeutic pipelines and antibody technologies.Finally, Cencora's acquisition of OneOncology for $5 billion underscores consolidation trends within specialty practice networks. By valuing OneOncology at $7.4 billion, this acquisition reflects the growing importance of integrated oncology care models and collaborative netSupport the show

2026 is going to be an exciting year for the GLP-1 space – you know it and I know it.Long dominated by the likes of Eli Lilly and Novo Nordisk, several other drugmakers are expected to challenge for market share. More drugmakers are coming in for a slice of that increasingly lucrative pie.We can never get enough conversation around GLP-1s, which is why we're capping 2025 with one more interview about this powerful class of drugs.​Katie Chlada, managing director at M+C Saatchi North America, joins us as our final podcast guest of the year. A self-described “GLP-1 evangelist” and “nerd,” Katie spoke with managing editor Jack O'Brien about what the future holds for these drugs, the access and affordability obstacles facing patients and how medical marketers can better communicate about these medications.And for our Trends segment, we have an interview from our recent AI Deciphered conference with Ian Cohen, head of creative and content, global communications at Ford Motor Company. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, HWP CEO Jani Hegarty and SVP of development operations Justin Schlemm share how Health & Wellness Partners is adopting AI internally — not as a trend, but with rigor, oversight and deep respect for the science and compliance that pharma demands. They discuss how AI is already helping HWP teams extract insights, and stay current on therapeutic trends — all within a strong framework of governance, integrity and human-in-the-loop quality control. The conversation explores how to separate novelty from necessity, and how life-science partners can confidently prepare for an AI-enabled future. Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here. Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharma Ads that Sound Ridiculous by Maine's Coast 93.1

Are you trying to break into medical sales but stuck deciding between Pharmaceutical and Medical Device? Or maybe you're curious about the high-growth world of Diagnostics and Genomics?Today, we discuss the differences in pay, lifestyle, and entry-level requirements for each path. Whether you want the adrenaline of the Operating Room or the stability of a $130k+ base salary in Pharma, this episode covers the 12 key distinctions you need to know before applying. IN THIS EPISODE YOU WILL LEARN:The Personality Test: Why "Engineers" love Device and "Scientists" love Pharma.The Paycheck: Real breakdown of base salaries vs. uncapped commissions.The Hidden Third Option: Why Oncology Diagnostics/Genomics might be the "Goldilocks" career path.Work-Life Balance: The reality of on-call surgical hours vs. the 9-to-5 pharma life.Success Stories: How a nurse (Sydney) and an immigrant (Kanika) broke in with $150k-$200k packages.READY TO BREAK IN? If you are struggling to get offers or don't know where to start, we help people from all backgrounds (nurses, coaches, teachers) launch their medical sales careers.Apply to Medical Sales U at medicalsalesu.com/TIMESTAMPS:00:00 - Intro: The common dilemma (O.R. vs. Samples).01:06 - The 3 Paths: Pharma, Device, and Diagnostics.02:15 - Science vs. Engineering: Which fits your brain?04:35 - Salary Reveal: Entry-level Pharma Pay ($95k-$135k base).06:10 - The "Associate" Role: Why Device base pay starts lower.07:40 - The Top 1%: Earning potential ($300k - $750k).09:15 - Diagnostics Pay: The sweet spot?10:30 - The Sales Process: Who are you actually selling to?13:50 - Lifestyle Check: Early mornings vs. Family flexibility.17:15 - Career Advancement: From Rep to Regional Director.22:15 - Student Success: From $68k to $200k total comp.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US:Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #PharmaceuticalSales #MedDevice #SalesCareer #DaveSterritt #CareerAdvice #HighPayingJobs #SalesTips

Steeds meer gezondheidsinformatie wordt continu gemeten, gewoon thuis of onderweg. Maar hoe vertaal je al die data uit sensoren, smartphones en wearables naar betrouwbare medische inzichten waar artsen en patiënten écht iets aan hebben? In deze aflevering van BNR Beter staat de opkomst van digitale biomarkers centraal: digitale metingen die inzicht geven in iemands gezondheid en ziekteverloop. Denk aan hartslag, hartritmevariabiliteit, slaap, beweging of loopsnelheid. Die biomarkers worden verzameld via sensoren en algoritmes, en steeds vaker ingezet om zorg persoonlijker, preventiever en minder afhankelijk van ziekenhuisbezoeken te maken. Presentator Nina van den Dungen gaat hierover in gesprek met twee experts uit het veld. Annika van Rosmalen, business developer Pharma & Digital Health bij TNO, legt uit hoe digitale biomarkers worden ontwikkeld, gevalideerd en toegepast in samenwerking met ziekenhuizen, patiëntenorganisaties en farmaceuten. Binnen het TNO Digital Biomarker Lab worden zulke meetmethoden getest en opgeschaald, met projecten rond onder meer type 2-diabetes, inflammatoire darmziekten en hart- en vaatziekten. Het doel: eerder signaleren, beter voorspellen en gerichter behandelen. Daarnaast schuift Bram den Teuling aan, oprichter en CEO van Orikami. Zijn bedrijf ontwikkelt een softwareplatform waarmee digitale biomarkers klinisch betrouwbaar kunnen worden ingezet, bijvoorbeeld bij multiple sclerose en in de oncologie. Den Teuling laat zien waarom juist de frequentie van meten, bijvoorbeeld via de sensoren in een smartphone, zoveel waarde oplevert, maar ook waarom medische software door strenge Europese regelgeving vaak jaren nodig heeft om de praktijk te bereiken. Samen bespreken zij de kansen en dilemma’s van digitale biomarkers:– Wat is het verschil tussen wellness-data en medisch gevalideerde metingen?– Welke rol spelen consumenten-wearables zoals smartwatches in de zorg?– Hoe ga je om met privacy en medische data, zeker als die via grote techbedrijven lopen?– En wat is er nodig om deze technologie écht te implementeren, voorbij pilots en experimenten?See omnystudio.com/listener for privacy information.

Shannon Davis, a Registered Dietitian Nutritionist with more than 19 years of experience specializing in metabolic health and insulin resistance. She's a founding board member of the American Diabetes Society, an Insulin IQ Coach, and the founder of a successful virtual metabolic health practice where she's helped nearly a thousand people reverse insulin resistance, lose weight, and even put type 2 diabetes into remission. Shannon's background spans dialysis, organ transplant, bariatrics, and pharmaceutical sales — giving her a unique perspective on why food, not medication, is the real solution to most dietary conditions. She's been featured on over 50 podcasts as an expert in metabolic health, and when she's not helping people transform their lives, you'll find her in the gym doing CrossFit or spending time riding horses — her lifelong passion. Instagram: https://www.instagram.com/sldavis6580 X: https://x.com/fittoeat6580 YouTube: https://youtube.com/@shannondavis1619 Facebook: https://www.facebook.com/shannon.davis.9279 Website: https://shannonfeelgreat.com/ Timestamps: 00:00 Trailer 00:53 Introduction 05:31 Renal care challenges and ethics 09:11 Kidney health and low-carb diets 10:41 Keto and kidney care 13:44 Dialysis conflict of interest 18:39 Diabetes advocacy and carnivore 21:16 Ketogenic diets and diabetes 24:02 Preventing heart disease 28:16 Diet wars and social media 31:26 Better living through medication 34:04 Platform censorship frustrations  37:14 Grassroots health movement challenges 42:51 AI transforming pharmaceutical marketing 43:30 Drug industry priorities  49:16 Low carb diet and cholesterol 50:29 Where to find Shannon 53:43 United in the fight Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

Allie interviews Dr. Josef Witt-Doerring, a psychiatrist and former FDA drug safety officer. He unveils the truth about Big Pharma and the detrimental side effects of medications for mental illnesses. SSRIs cause more harm than good; they blunt emotions, breed dependency, and often backfire long-term. Dr. Witt-Doerring advises patients to pursue holistic health that includes a balanced diet, sleep, exercise, and therapy. He and his wife have started TaperClinic, where they help people come off medications and find real solutions to their problems. Join us for an eye-opening discussion about the dark side of the pharmaceutical industry. Check out more about Dr. Witt-Doerring's TaperClinic here: ⁠taperclinic.com⁠ Buy Allie's book "Toxic Empathy: How Progressives Exploit Christian Compassion": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.toxicempathy.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Timecodes: (00:00) Intro (09:45) Misdiagnosing Mental Illness (19:20) Drug Safety Officer (25:05) Corruption in Medical Academia (27:50) Wake-Up Call (34:35) Problems with SSRIs (46:00) Short-Term vs. Long-Term Medication (53:50) TaperClinic --- Today's Sponsors: PreBorn — Would you consider a gift to save babies in a big way? Your gift will be used to save countless babies for years to come. To donate, dial #250 and say the keyword BABY or donate securely at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠preborn.com/allie⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Good Ranchers — Give a reason to gather. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠goodranchers.com⁠⁠⁠⁠⁠⁠⁠⁠⁠ to start gifting, and while you're there, treat yourself with your own subscription to America's best meat. And when you use the code ALLIE, you'll get $40 off your first order. EveryLife — Visit ⁠⁠⁠⁠⁠everylife.com⁠⁠⁠⁠⁠ and use promo code ALLIE10 to get 10% off your first order today!  Patriot Mobile — Switching to Patriot Mobile is easier than ever. Activate in minutes from your home or office. Keep your number, keep your phone, or upgrade. Go to ⁠⁠⁠patriotmobile.com/allie⁠⁠⁠ or call 972-PATRIOT, and use promo code ALLIE for a free month of service! Cozy Earth — Give the gift of everyday luxury this holiday season. Head to ⁠cozyearth.com⁠ and use the code RELATABLE for up to 40% off — just be sure to place your order by December 12 for guaranteed Christmas delivery. --- Episodes you might like:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ep 1189 | SSRIs Are Rewiring Babies' Brains — and Killing Their Moms | Guest: Dr. Adam Urato ⁠https://podcasts.apple.com/us/podcast/ep-1189-ssris-are-rewiring-babies-brains-and-killing/id1359249098?i=1000708507649⁠ Ep 821 | Why Antidepressants Don't Fix Depression | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-821-why-antidepressants-dont-fix-depression-guest/id1359249098?i=1000616890403⁠⁠ Ep 822 | The Big Money Behind Big Medicine | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-822-the-big-money-behind-big-medicine-guest-dr/id1359249098?i=1000617050991⁠⁠ Ep 1031 | Psychiatry Is Killing People | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-1031-psychiatry-is-killing-people-guest-dr-roger/id1359249098?i=1000661830317⁠⁠ --- Buy Allie's book "You're Not Enough (and That's Okay): Escaping the Toxic Culture of Self-Love": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.alliebethstuckey.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Relatable merchandise: Use promo code ALLIE10 for a discount: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://shop.blazemedia.com/collections/allie-stuckey⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Mehr als eine Milliarde Menschen im globalen Süden leidet an Wurmkrankheiten. Die Folgen: Unter anderem Blutarmut, Arbeitsunfähigkeit und Entwicklungsstörungen bei Kindern. Von Martina Keller.

This episode features Olivier Godement, Head of Product for Business Products at OpenAI, discussing the current state and future of AI adoption in enterprises, with a particular focus on the recent releases of GPT 5.1 and Codex. The conversation explores how these models are achieving meaningful automation in specific domains like coding, customer support, and life sciences: where companies like Amgen are using AI to accelerate drug development timelines from months to weeks through automated regulatory documentation. Olivier reveals that while complete job automation remains challenging and requires substantial scaffolding, harnesses, and evaluation frameworks, certain use cases like coding are reaching a tipping point where engineers would "riot" if AI tools were taken away. The discussion covers the importance of cost reduction in unlocking new use cases, the emerging significance of reinforcement fine-tuning (RFT) for frontier customers, and OpenAI's philosophy of providing not just models but reference architectures and harnesses to maximize developer success. (0:00) Intro(1:46) Discussing GPT-5.1(2:57) Adoption and Impact of Codex(4:09) Scientific Community's Use of GPT-5.1(6:37) Challenges in AI Automation(8:19) AI in Life Sciences and Pharma(11:48) Enterprise AI Adoption and Ecosystem(16:04) Future of AI Models and Continuous Learning(24:20) Cost and Efficiency in AI Deployment(27:10) Reinforcement Learning and Enterprise Use Cases(31:17) Key Factors Influencing Model Choice(34:21) Challenges in Model Deployment and Adaptation(38:29) Voice Technology: The Next Frontier(41:08) The Rise of AI in Software Engineering(52:09) Quickfire With your co-hosts: @jacobeffron - Partner at Redpoint, Former PM Flatiron Health @patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn @ericabrescia - Former COO Github, Founder Bitnami (acq'd by VMWare) @jordan_segall - Partner at Redpoint

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of the Trade Guys, Bill and Scott  unpack a proposal from the Trump administration to give a $2,000 tariff dividend to all low- and middle-income Americans. They also examine a new deal between the U.S. and UK on pharmaceuticals. Finally, we finish with a debate on whether bullying or persuasion is more effective in trade negotiations.

If you are making it to the panel interview but still getting those automated "Thanks but no thanks" emails, you are likely making one of these 3 fatal mistakes.In this episode, we reveal why high-achievers like nurses, D1 athletes, and experienced VPs fail to break into Pharma and Medical Device sales. WHAT YOU WILL LEARN IN THIS EPISODE:- The "Immature Enthusiasm" Trap: Why being a "go-getter" isn't enough and the specific clinical research you MUST do before the first phone call.- The LinkedIn Strategy: Stop using LinkedIn like a digital resume. Learn the "20-Person Rule" and how to message hiring managers without being annoying.- The "Guard Down" Mistake: Why you are failing the field ride and peer interviews (and why you should never relax around potential colleagues).CHAPTERS (Jump to the section you need):0:00 - Intro: Why talented people get rejected01:50 - Mistake #1: You Didn't Do the Research (FDA, Clinical Trials, Competitors)04:44 - Immature Enthusiasm vs. Professional Readiness05:12 - Mistake #2: You Are Using LinkedIn Wrong (Stop asking to "Pick their brain")06:35 - The "20-Person" LinkedIn Strategy12:33 - Mistake #3: You Are Not Networking Correctly (The "Invisible" Applicant)13:43 - Warning: The "Guard Down" Trap with Peer Reps ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US:Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #PharmaceuticalSales #CareerAdvice #SalesInterview #MedicalSalesU #JobSearchTips #LinkedInStrategy

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Not gonna give much of an introduction here because this is a short bonus level set, but I did just wanna call everyone's attention to the "arms race" created by our status quo purchasing and selling of many things, pharmaceuticals included. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For example, raise the list price of a drug to maximize rebates, because the higher the list, the bigger the discount you can give, which then exacerbates patient affordability because coinsurance is often based on list price. But then Pharma starts offering co-pay cards, which messes up the whole PBM (pharmacy benefit manager) plan to drive patients to their highest-rebate products (ie, the most profitable products). So then maximizers and accumulators enter the chat, and prior auths ramp up because plans start having to raise premiums after enough 340B drugs with high lists and no rebates, and then there's no cost containment and raise deductibles and around and around we go. Meanwhile, is this drug fundamentally worth the list price or even the net price? Is it an effective drug? What's the right price to be paying for this drug? Should be the operative question, right? Just like what's the quality and appropriateness of any medical service? Maybe we should just quit it and just pay for value. And with that, let me introduce Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review), and I will let Sarah tell the rest of the story. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Payerset; Aventria Health Group; Dea Belazi, PharmD, MPH; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   02:28 What is ICER? 02:47 What does the Institute for Clinical and Economic Review do? 05:09 The importance of still showing up, even when others don't understand or disagree. 06:51 EP293 ("Game Theory Gone Wild") with Dea Belazi, PharmD, MPH. 09:04 Why it's important to think about population health and how our choices impact affordability for everyone.   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #ICER and the status quo of #pharmaceuticaldrug #pricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl  

I was out drinking martinis with Cora Opsahl, director of 32BJ Health Fund, and Cora said, "Look, most plan sponsors' biggest expense is health system spend, hospital spend." I know this is an unexpected start to an episode about pharmaceutical pricing and value featuring Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review). But yeah, 50% of most plan sponsors' spend these days goes to health systems. Fifty percent! One half! For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. So, if a patient who is adherent to a drug and that drug keeps that patient out of the hospital, why do I want to make a patient have excessive skin in the game to get that drug, which everybody knows at this point this "skin in the game" can cause said patient to not be adherent in many cases, cost being a very big reason patients give for not taking medications as prescribed. So then we have this not adherent patient who winds up in the hospital, via the ER often enough. The core issue here that surfaced, bottom line—and I'm not sure if this was in spite of the martinis or as a result of them—but while hospital spend is the largest health expense, high-value drugs that prevent hospitalization often face patient cost sharing and access restrictions, which leads to poor patient adherence and ultimately higher system cost potentially. So then Cora and I spent the next half hour debating when the statement is empirically true and when it's not. And you know what it all boils down to? What's the value of the drug? Do we even know what that means to start? But if it's determined that the drug is relatively high value, then the plan desperately should want to do everything possible to keep that patient on that medication, and cost sharing is a huge barrier to adherence. Today, as I said, I'm speaking with Sarah Emond, CEO over at ICER, and we get into all of this in the conversation that follows. In fact, most of the conversation that follows explores the tensions that exist in the current way that we sell and buy pharmaceutical products. I'm just gonna sum up these tensions in a list here at the top of this show. There's six of them that Sarah Emond and I discussed today by my counting, and each of these we explore in some depth. So, here's the list. Tension 1: The value of any given drug (in other words, what is the fair price for that drug considering the health gains that it delivers) versus the total cost to the plan for the total population taking that drug. GLP-1s have entered the chat. GLP-1s (by ICER's analysis, at least) are super high-value drugs that also can bankrupt plans due to the number of folks who may benefit from taking the drug. Definitely a tense tension to kick off our list here. Tension 2: The list or net price of a drug versus patient access and affordability. Again, this can be tense in an area of much misalignment. You can have a great well-priced drug with huge patient affordability and access challenges because drug net price and coinsurance amounts often have nothing to do with each other. Tension 3: Lifetime value of a drug versus a 3-, 2.5-year, whatever time horizon that many plan sponsor actuaries use in their value assessment. We discussed this today, but there's a Summer Short (SUMS7) on actuarial value horizons with Keith Passwater and JR Clark if you wanna dig in on this further. Tension 4: The tension between the societal value of a drug or even the patient's perceived value of a drug versus what an employer plan sponsor might perceive as the value. What is the formula used to determine value? What's in and what's out? So, that's a bigger conversation just beyond the time horizon for what's included in this calculation. Tension 5: Exacerbating the what's included in the value contemplation beyond just what you include in there is the tension between what is hypothetically of value and what is possible to measure. If you have pharma datasets and medical datasets separate in silos, who knows how many hospital readmissions were prevented by whatever drug? And how much presenteeism or absenteeism exists. I mean, it is an outlier, again, if anyone even knows the net price they paid for a drug, just to level set context here. Tension 6: Lowering financial barriers for patients to take drugs that are of value versus status quo goals and incentives. Like, for example, PBMs (pharmacy benefit managers) are often told that their goal is to reduce drug spend. Okay … so, how do I do that? Oh, reduce access either by prior auths or delay tactics or really high coinsurance, which is gonna reduce adherence by design. And it's someone else's problem—if I'm just thinking like a status quo PBM—if medical spend goes up, right? So, that's our last and not insignificant tension. And look, who comes out the loser in all of these tensions when they get tense? Patients. Not pricing based on value and not buying and setting up cost sharing based on value punishes patients and also plan sponsors or any other ultimate purchaser in the long term, given that the plan is but a population of patients if you start thinking about it in that context. Here is Sarah's advice in a nutshell: Pharma, sell. Pick your price based on something other than market power. And some pharma companies are actually dipping their toe into these waters and doing it. But then PBMs and plan sponsors have to hold up their end of the bargain here and buy drugs based on their value, not just the size of their rebates or some other discounting promise. And then we gotta continue the through line through to member affordability and access. High-value drugs should get preferred. So, right, do a high-value formulary. Listen to the show with Nina Lathia, RPh, MSc, PhD (EP426) on high-value formularies and then listen (after you're done with that one) to episode 435 with Dan Mendelson entitled "Optimized Pharmacy Benefits Are Required if You Want to Do or Buy Value-Based Care." Also, as I said, GLP-1s come up in this conversation, so … yeah, buckle up. One last thing, besides my normal thank you to Aventria Health Group for sponsoring this episode, I am so pleased to thank Payerset for donating to help Relentless Health Value stay on the air. Payerset is a price transparency company with a mission to create fair and equitable healthcare for everyone. Love that. Payerset empowers healthcare organizations, employers, and patients with the most complete set of healthcare price transparency data. They benchmark every negotiated rate and claim and delivering the actionable insights needed for smarter contract negotiations and a more transparent healthcare system. As I have said several times today, my conversation is with Sarah Emond, CEO of ICER. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Keith Passwater; JR Clark; Nina Lathia, RPh, MSc, PhD; Dan Mendelson; Aventria Health Group; Payerset; Antonio Ciaccia; Elizabeth Mitchell; Purchaser Business Group on Health (PBGH); Shane Cerone; Sam Flanders, MD; Mark Cuban; Morgan Health; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   08:18 Why list prices are a lie. 10:59 How does the rebate model sometimes get in the way of paying for value? 12:50 Bonus clip with Sarah Emond. 13:14 EP491 with Elizabeth Mitchell. 13:20 EP490 and EP492 with Shane Cerone and Sam Flanders, MD. 14:37 The tension that is created between affordability and adherence. 15:03 When cost sharing makes sense in pharmaceutical drug pricing. 17:26 INBW42 with Stacey on moral hazard. 18:53 How GLP-1s are "wildly cost effective." 21:32 Why the sticker shock on cost-effective drugs is a failure in the system for paying for value. 22:38 ICER's report on GLP-1s. 26:59 EP385 with Dan Mendelson. 28:57 How employers and payers can have a value assessment approach and a health insurance system that allows access to cost-effective drugs. 29:48 How cost-effective prices are calculated. 31:55 One of the core value underpinnings for value assessment of drugs. 34:54 Why manufacturers and pharmacy benefit managers should work together more by referencing something like an ICER report. 36:55 EP426 with Nina Lathia, RPh, MSc, PhD. 38:21 "We can make different choices."   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #pharmaceutical #drugpricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl

Pharma deal, Supreme Court on piracy, special election in Nashville, and a TSA record. Plus, the Message of the Day, on heaven and hell… Learn more about your ad choices. Visit megaphone.fm/adchoices

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.